Product Overview:
KPV (Lysine-Proline-Valine) is a tripeptide fragment of the melanocortin hormone α-MSH and is studied for its potent anti-inflammatory and immune-regulatingproperties in epithelial tissues. It does not stimulate melanogenesis, making it a favorable candidate for research into localized inflammation control without pigmentary effects.
Research shows that KPV interacts with melanocortin receptors (MC1R) to inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, making it of interest in models related to:
-
Inflammatory bowel conditions
-
Dermatological inflammation
-
Wound healing and epithelial regeneration
Applications in Research:
-
Investigation of mucosal inflammation and gut epithelial healing
-
Research on cytokine suppressionand immune signaling
-
Models of topical or systemic inflammation control
-
Epithelial barrier recovery in skin or GI tract
Storage & Handling:
Store lyophilized peptide at -20°C in a sealed, dry, light-protected vial.
Reconstitute with bacteriostatic water under sterile lab conditions. Store reconstituted solution refrigerated and use promptly. Avoid multiple freeze-thaw cycles.
RESEARCH USE ONLY – LEGAL DISCLAIMER
All Nivo Labs products labeled as Research Use Only (RUO) are intended strictly for laboratory, investigational, and scientific research purposes. These materials are not approved by the FDA and are not intended for human or veterinary use, clinical applications, diagnostic procedures, or therapeutic treatment of any kind.
By purchasing or using RUO materials, you acknowledge that they will be handled only within an appropriate research environment by qualified personnel who understand the risks, limitations, and regulatory requirements associated with experimental compounds. Products must not be administered to humans or animals, offered as therapeutic agents, or represented as safe or effective for any medical purpose.
Use of these materials is entirely at your own risk. Nivo Labs assume no liability for misuse, unsafe handling, improper application, or any regulatory or compliance issues arising from their use.
